Novo Nordisk’s primary business area, dubbed Diabetes Care, fared worse than expected in the second quarter of 2022. The Ozempic drug once again generated higher-than-expected growth but Rybelsus disappointed compared to analyst estimates, the firm’s accounting report for the period showed Wednesday.
Overall diabetes revenue at Novo Nordisk totaled DKK 32.4bn (USD 4.4bn) in Q2 compared to DKK 26bn (USD 3.6bn) in the same period last year. This falls short of the analyst consensus estimate of DKK 32.6bn (USD 4.5bn) calculated by the pharmaceutical firm before the report was released.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
ALK to exit Turkish market: "It's bad business if all we get is peanuts"
A number of conditions made it unfeasible for the Danish allergy firm to do business in Türkiye, says CEO Carsten Hellmann. Under a calculated and ruthless strategy to focus on markets with momentum, efforts in Italy and Spain have also been reduced.
Genmab postpones crucial cancer candidate decision following Abbvie exit
For the rest of 2022, the Danish biotech firm will share all expenses relating to the development of Duohexabody-CD37 with Abbvie, despite the US-based firm’s decision to withdraw from the collaboration in question.
Genmab says new arbitration builds on a straightforward question
”I think this is a much simpler case than the first arbitration,” says Genmab CEO Jan van de Winkel on the new legal suit brought against Janssen, which stems from a fight Genmab has already lost once.
Top news from MedWatch this week
Miss anything?
Analyst: Upgraded ALK sales guidance could still be beaten
Despite an upgrade, ALK may still beat its own sales guidance, one Sydbank analyst predicts.
IT QA Manager 
Senior Clinical Trial Manager - Black Swans Exist 
Open position for a Clinical Trial Manager to join our team at Nykode! 
Antibody Engineering Scientist 
QA Manager, QA Commercial Operations, Ascendis Pharma 
Sales Director, Nordic Hospital Solutions, at Mediq Denmark 
Scientist Radiochemistry 
Quality coordinator for Aseptic Production, ALK 
Clinical Biometrics Oversight Lead 
Director Regulatory Affairs 
Lead Auditor – Senior Quality Assurance Specialist 
GMP Compliance Consultant for Eltronic in Ballerup 
Clinical Trial Manager - Black Swans Exist